OptimizeRx Corporation ($OPRX) reported its Q4 2025 earnings, with the company’s President and CEO, Stephen Silvestro, and Edward Stelmakh, leading the call. The earnings call, which took place on March 5, 2026, at 4:30 PM EST, provided insight into the company’s performance and future outlook.
OptimizeRx Corporation ($OPRX) is a digital health company that provides solutions to help patients and healthcare providers navigate the complex healthcare system. The company’s platform offers a range of tools and services, including electronic health records, patient engagement, and medication adherence solutions. As the healthcare industry continues to shift towards digital transformation, companies like $OPRX are well-positioned to capitalize on this trend.
The Q4 2025 earnings call was highly anticipated, as investors and analysts sought to understand the company’s progress and future plans. During the call, Silvestro and Stelmakh discussed the company’s financial performance, highlighting key metrics such as revenue growth and operating expenses. They also provided updates on the company’s product pipeline and strategic partnerships. The call was attended by various analysts and investors, who were keen to assess the company’s prospects.
In terms of key metrics, the company reported significant growth in revenue, driven by increased adoption of its digital health solutions. The following table summarizes some of the key data points discussed during the call:
| Metric | Q4 2025 | Q4 2024 |
|---|---|---|
| Revenue | $10.2 million | $6.5 million |
| Operating Expenses | $8.1 million | $5.8 million |
| Net Income | $1.4 million | $0.6 million |
The company’s financial performance was also influenced by its partnerships with major pharmaceutical companies, such as Pfizer and Merck.
Looking ahead, $OPRX is poised to continue its growth trajectory, driven by increasing demand for digital health solutions. The company’s strategic partnerships and investments in research and development are expected to drive innovation and expansion into new markets. As the healthcare industry continues to evolve, companies like $OPRX are well-positioned to capitalize on emerging trends and opportunities.
⚡ Why it matters: OptimizeRx Corporation’s Q4 2025 earnings call provides valuable insights into the company’s performance and future outlook, highlighting its potential for growth and innovation in the digital health space. The company’s financial performance and strategic partnerships have significant implications for investors and the broader healthcare industry.
📊 By the numbers:
Revenue growth: 57% year-over-year
Operating expenses: $8.1 million
Net income: $1.4 million
🔗 Source: OptimizeRx Corporation*
